Showing results (1051-1060 of 1,996) with videos related to

Sort By:
Pageof 200
The Lancet. Neurology|March 22, 2020
Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trialMasayuki Tahara, Tomoko Oeda, Kazumasa Okada, et al.
The Lancet. Neurology|June 18, 2022
Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trialMessoud Ashina, Michel Lanteri-Minet, Patricia Pozo-Rosich, et al.
The Lancet. Neurology|May 8, 2022
Surgery versus conservative treatment for traumatic acute subdural haematoma: a prospective, multicentre, observational, comparative effectiveness studyThomas A van Essen, Hester F Lingsma, Dana Pisică, et al.
The Lancet. Neurology|June 21, 2017
Prediction of cognition in Parkinson's disease with a clinical-genetic score: a longitudinal analysis of nine cohortsGanqiang Liu, Joseph J Locascio, Jean-Christophe Corvol, et al.
The Lancet. Neurology|June 24, 2017
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association studyDavina J Hensman Moss, Antonio F Pardiñas, Douglas Langbehn, et al.
The Lancet. Neurology|September 21, 2016
Insomnia, parasomnias, and narcolepsy in children: clinical features, diagnosis, and managementKiran Maski, Judith A Owens
The Lancet. Neurology|June 25, 2017
Anterior pallidal deep brain stimulation for Tourette's syndrome: a randomised, double-blind, controlled trialMarie-Laure Welter, Jean-Luc Houeto, Stéphane Thobois, et al.
The Lancet. Neurology|October 23, 2021
Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trialPatrick Gavin Kehoe, Nicholas Turner, Beth Howden, et al.
The Lancet. Neurology|October 23, 2021
Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trialAntonio Uccelli, Alice Laroni, Rehiana Ali, et al.
The Lancet. Neurology|April 17, 2022
Functional neurological disorder: new subtypes and shared mechanismsMark Hallett, Selma Aybek, Barbara A Dworetzky, et al.
Pageof 200